NeoPharm Co Ltd
KOSDAQ:092730
NeoPharm Co Ltd
Cost of Revenue
NeoPharm Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
NeoPharm Co Ltd
KOSDAQ:092730
|
Cost of Revenue
-₩35.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
AmorePacific Corp
KRX:090430
|
Cost of Revenue
-₩1.1T
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
Amorepacific Group
KRX:002790
|
Cost of Revenue
-₩1.1T
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Cosmax Inc
KRX:192820
|
Cost of Revenue
-₩1.6T
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
LG H&H Co Ltd
KRX:051900
|
Cost of Revenue
-₩3.2T
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Cost of Revenue
-₩1.6T
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-18%
|
See Also
What is NeoPharm Co Ltd's Cost of Revenue?
Cost of Revenue
-35.4B
KRW
Based on the financial report for Mar 31, 2024, NeoPharm Co Ltd's Cost of Revenue amounts to -35.4B KRW.
What is NeoPharm Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-21%
Over the last year, the Cost of Revenue growth was -30%. The average annual Cost of Revenue growth rates for NeoPharm Co Ltd have been -13% over the past three years , -13% over the past five years , and -21% over the past ten years .